-
公开(公告)号:MX2011006608A
公开(公告)日:2011-07-12
申请号:MX2011006608
申请日:2009-12-18
Applicant: BAXTER INT
Inventor: MIN KYUNGYOON , BACKLES LARRY , RAUSA FRANCISCO M III , BAIRSTOW SHAWN F , RAMACHANDRAN SINDHU , POKROPINSKI SHARON
Abstract: La presente descripción se refiere en general a sistemas para obtener una inmunoglobulina farmacéuticamente aceptable a partir de sangre de un donador, que comprenden un primer conducto configurado para transportar sangre del donador a un substrato, en donde dicha sangre incluye al menos un primer componente y al menos un segundo componente, dicho primer componente de la sangre incluyendo inmunoglobulina, y en donde dicho substrato está adaptado para unir inmunoglobulina; y un segundo conducto configurado para transportar al menos una porción del segundo componente de la sangre a partir del primer conducto hacia el donador.
-
公开(公告)号:ES2474740T3
公开(公告)日:2014-07-09
申请号:ES09795646
申请日:2009-12-18
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: MIN KYUNGYOON , BACKES LARRY , RAUSA FRANCISCO M , BAIRSTOW SHAWN F , RAMACHANDRAN SINDHU , POKROPINSKI SHARON
Abstract: Sistema para obtener un producto de inmunoglobulina farmacéuticamente aceptable a partir de sangre de un donante, que incluye: un sustrato adaptado para unirse a inmunoglobulina; un primer conducto configurado para transportar sangre o un componente sanguíneo desde del donante hasta el sustrato, incluyendo dicha sangre o componente sanguíneo al menos un primer componente y al menos un segundo componente, y comprendiendo dicho primer componente inmunoglobulina; un segundo conducto configurado para transportar al menos una parte del segundo componente de la sangre o componente sanguíneo desde el primer conducto hasta el donante; un tercer conducto configurado para transportar un producto de inmunoglobulina aislado de dicho sustrato; y un cuarto conducto configurado para transportar el producto directamente a un receptor.
-
公开(公告)号:SG187599A1
公开(公告)日:2013-03-28
申请号:SG2013005640
申请日:2011-07-22
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: BAIRSTOW SHAWN F , HUTSELL JENNIFER , RAMACHANDRAN SINDHU
Abstract: The present invention provides compositions and pharmaceutical formulations of lalp derived from plasma. Also provided are methods for the manufacture of the lalp compositions and formulations, as well as method for the treatment of diseases associated with lalp dysfunction.
-
公开(公告)号:HK1170679A1
公开(公告)日:2013-03-08
申请号:HK12111567
申请日:2012-11-14
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: RABINOW BARRETT , BAIRSTOW SHAWN F , CHAUBAL MAHESH V , LEE SARAH , WERLING JANE
IPC: A61P20060101 , A61K20060101
Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm:
-
公开(公告)号:BR112013001753A2
公开(公告)日:2016-05-31
申请号:BR112013001753
申请日:2011-07-22
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor: HUTSELL JENNIFER , BAIRSTOW SHAWN F , MACHANDRAN SINDHU
IPC: C07K14/81
Abstract: método para preparar uma composição de inter-alfa-inibidor (iaip) enriquecida de plasma, solução aquosade iaip, e, métodos para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividade de protease de serina no plasma aumentada. a presente invenção fornece composições e formulações farmacêuticas de iaip derivadas de plasma. também são fornecidos métodos para a fabricação das composições e formulações de iaip, bem como método para o tratamento de doenças associadas à disfunção de iaip.
-
公开(公告)号:BRPI1010903A2
公开(公告)日:2016-03-15
申请号:BRPI1010903
申请日:2010-05-13
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor: RABINOW BARRETT , WERLING JANE , CHAUBAL MAHESH V , LEE SARAH , BAIRSTOW SHAWN F
IPC: A61K9/14 , A61K31/337 , A61K47/34 , A61P35/00
-
公开(公告)号:ES2509919T3
公开(公告)日:2014-10-20
申请号:ES10719211
申请日:2010-05-13
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: RABINOW BARRETT , BAIRSTOW SHAWN F , CHAUBAL MAHESH V , LEE SARAH , WERLING JANE
IPC: A61K9/14 , A61K31/337 , A61K31/365 , A61K31/415 , A61K31/427 , A61K31/444 , A61K31/496 , A61K31/513 , A61K31/538 , A61K31/551 , A61K31/708 , A61K47/34 , A61P35/00
Abstract: Partícula de superficie modificada que comprende un núcleo de partícula y un revestimiento asociado al núcleo de partícula, comprendiendo el núcleo de partícula un principio activo seleccionado de entre el grupo consistente en moléculas pequeñas, péptidos y proteínas, comprendiendo el revestimiento un agente tensioactivo de fórmula I o una sal del mismo, y presentando la partícula de superficie modificada un tamaño medio entre aproximadamente 1 nm y aproximadamente 2.000 nm: donde n y m son 1; R1, R2 y R3 son metilo; y R4 y R5 se seleccionan independientemente entre el grupo consistente en cis-9-octadecenoílo y cis-9- octadecenilo.
-
公开(公告)号:AU2010249008B2
公开(公告)日:2014-06-05
申请号:AU2010249008
申请日:2010-05-13
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor: RABINOW BARRETT , BAIRSTOW SHAWN F , CHAUBAL MAHESH V , LEE SARAH , WERLING JANE
IPC: A61K9/14 , A61K31/337 , A61K47/34 , A61P35/00
Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula (I) or a salt thereof, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm:
-
公开(公告)号:AU2013204469A1
公开(公告)日:2013-05-09
申请号:AU2013204469
申请日:2013-04-12
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: MIN KYUNGYOON , BACKES LARRY , RAUSA III FRANCISCO M , BAIRSTOW SHAWN F , RAMACHANDRAN SINDHU , POKROPINSKI SHARON
Abstract: A system for obtaining a pharmaceuticaly acceptable immunoglobulin product from blood of a donor including a first conduit configured to convey blood or blood component from the donor to a substrate, wherein said blood or blood component includes at least one first component and at least one second component, said first component inckding immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; a second condL it configured to convey at least a portion of the second component of the blood or blood component from the first conduit to the donor; a third conduit configured to convey an immunoglobulin product isolated frm said substrate; and a fourth conduit configured to convey the product directly to a recipient
-
公开(公告)号:CA2806645A1
公开(公告)日:2012-01-26
申请号:CA2806645
申请日:2011-07-22
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor: BAIRSTOW SHAWN F , HUTSELL JENNIFER , RAMACHANDRAN SINDHU
IPC: C07K14/81
Abstract: The present invention provides compositions and pharmaceutical formulations of lalp derived from plasma. Also provided are methods for the manufacture of the lalp compositions and formulations, as well as method for the treatment of diseases associated with lalp dysfunction.
-
-
-
-
-
-
-
-
-